166 related articles for article (PubMed ID: 17396743)
1. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
Dasanu CA; Alexandrescu DT; Dutcher J
South Med J; 2007 Mar; 100(3):328-30. PubMed ID: 17396743
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
3. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
4. Acute pancreatitis associated with sorafenib.
Li M; Srinivas S
South Med J; 2007 Sep; 100(9):909-11. PubMed ID: 17902294
[TBL] [Abstract][Full Text] [Related]
5. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
[No Abstract] [Full Text] [Related]
6. Sorafenib induced eruptive melanocytic lesions.
Uhlenhake EE; Watson AC; Aronson P
Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
[TBL] [Abstract][Full Text] [Related]
7. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
Ikeda M; Fujita T; Mii S; Tanabe K; Tabata K; Matsumoto K; Satoh T; Iwamura M
Jpn J Clin Oncol; 2012 Sep; 42(9):820-4. PubMed ID: 22782962
[TBL] [Abstract][Full Text] [Related]
8. Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib.
Sahai S; Swick BL
Int J Dermatol; 2010 Oct; 49(10):1203-6. PubMed ID: 20883411
[TBL] [Abstract][Full Text] [Related]
9. Managing adverse events associated with sorafenib in renal cell carcinoma.
Edmonds K; Spencer-Shaw A
Br J Nurs; 2010 Jan 14-27; 19(1):58-60. PubMed ID: 20081715
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib-induced erythema multiforme: three cases.
Namba M; Tsunemi Y; Kawashima M
Eur J Dermatol; 2011; 21(6):1015-6. PubMed ID: 21926043
[No Abstract] [Full Text] [Related]
11. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
12. A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
Berchem G; Dewilde S; Mahassen P
Bull Soc Sci Med Grand Duche Luxemb; 2009; (1):7-9. PubMed ID: 19514172
[TBL] [Abstract][Full Text] [Related]
13. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
[TBL] [Abstract][Full Text] [Related]
14. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
Xie XD; Piao Y; Liu ZZ
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):714-5. PubMed ID: 20021872
[No Abstract] [Full Text] [Related]
15. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
Beldner M; Jacobson M; Burges GE; Dewaay D; Maize JC; Chaudhary UB
Oncologist; 2007 Oct; 12(10):1178-82. PubMed ID: 17962611
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Bukowski RM
Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
[No Abstract] [Full Text] [Related]
17. Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
Kodaira M; Takahashi S; Takeuchi K; Yuasa T; Saotome T; Yonese J; Fukui I; Hatake K
Ann Oncol; 2010 Jul; 21(7):1563-1565. PubMed ID: 20573851
[No Abstract] [Full Text] [Related]
18. Sorafenib-induced palmoplantar hyperkeratosis.
Lountzis NI; Maroon MS
J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
Sibaud V; Delord JP; Chevreau C
Target Oncol; 2009 Dec; 4(4):307-10. PubMed ID: 19894099
[TBL] [Abstract][Full Text] [Related]
20. Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib.
Cicek D; Kandi B; Dagli FA; Karaoglu A; Haligur BD
Clin Drug Investig; 2008; 28(12):803-7. PubMed ID: 18991474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]